# Changes in symptom burden and quality of life among women with uterine fibroids receiving relugolix combination therapy: a plain language summary

## TL;DR

This study found that relugolix combination therapy reduced symptoms and improved quality of life for women with uterine fibroids.

## Contribution

The study provides new evidence on the effectiveness of relugolix in improving health-related quality of life in women with uterine fibroids.

## Key findings

- More women reported less distress from uterine fibroid symptoms after taking relugolix combination therapy.
- Health-related quality of life improved significantly in women treated with relugolix compared to placebo.
- Relugolix combination therapy was associated with better symptom management and quality of life outcomes.

## Abstract

This is a summary of findings from two research studies (known as clinical trials). The studies looked at how well a medicine called relugolix combination therapy worked in women with heavy menstrual bleeding (heavy bleeding during a period) with uterine fibroids (noncancerous or benign growths in the uterus). In this analysis of the studies, researchers looked at how patients self-reported their uterine fibroid symptoms before and after taking relugolix combination therapy. Researchers also looked at how patients self-reported the impact of uterine fibroids on their health-related quality of life before and after taking relugolix combination therapy.

Women took either relugolix combination therapy or placebo (a pill that contains no medicine) by mouth once daily for 24 weeks. Women completed the Uterine Fibroid Symptom and Quality of Life questionnaire (where “quality of life” refers to the women's health-related quality of life related to uterine fibroids) before, during, and after treatment. The questionnaire let researchers see if the women felt that relugolix combination therapy decreased the burden of uterine fibroid symptoms and improved the women's health-related quality of life related to uterine fibroids. More women said that they felt less distress due to their uterine fibroid symptoms and that their health-related quality of life related to uterine fibroids was better after taking relugolix combination therapy compared with women who took placebo.

Relugolix combination therapy may lessen distress associated with uterine fibroid symptoms and improve health-related quality of life related to uterine fibroids.